Dosing Strategies and Disease Control With Ponatinib: The OPTIC Study
An expert explores findings of the OPTIC study, revealing optimal dosing strategies for ponatinib in CML treatment, including insights into dose reduction and patient response based on T315I mutation status.
Biochemical and Clinical Progression: The Two Faces of Relapsed MM
Andrew Cowan, MD, discusses the complexities of relapsed multiple myeloma, distinguishing between biochemical and clinical progression, analyzing survival data, and raising questions about optimal treatment strategies.
Team Introductions: MM Experts From the Fred Hutchinson Cancer Center and City of Hope
An overview of the program agenda and introduction of expert panelists from the Fred Hutchinson Cancer Center and City of Hope teams.
Optimizing Ponatinib in CML: Understanding AOEs in the PACE Trial
A retrospective analysis of arterial occlusive events in the PACE trial, shedding light on risk factors and management strategies for ponatinib treatment in CML patients.
Team Introductions: CML Experts From the Fred Hutchinson Cancer Center and City of Hope
An overview of the program agenda and introduction of expert panelists from the Fred Hutchinson Cancer Center and City of Hope teams.